Innovative Medicine — Other (income) expense, net
Business Segments · Other (income) expense, netJohnson & Johnson Innovative Medicine — Other (income) expense, net decreased by 2728.6% to -$368.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 137.4%, from -$155.00M to -$368.00M. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Other (income) expense, net shows a downward trend with a -46.6% CAGR.
Analysis
StatementSegment
CategoryProfitability
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ3 2025
How to read this metric
Large fluctuations can indicate one-time events like legal settlements, asset disposals, or non-core financial gains.
Detailed definition
Includes non-operating items such as interest income, gains or losses on asset sales, and other miscellaneous financial...
Peer comparison
Commonly reported as 'Other Operating Income/Expense' in segment-level financial reporting.
Metric ID:
jnj_segment_innovative_medicine_other_income_expense_netHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $373.50M | $373.50M | $373.50M | $373.50M | $248.25M | $248.25M | $248.25M | $248.25M | -$111.00M | $41.00M | -$155.00M | -$201.00M | -$166.00M | $14.00M | -$368.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -33.5% | +0.0% | +0.0% | +0.0% | -144.7% | +136.9% | -478.0% | -29.7% | +17.4% | +108.4% | <-999% |
| YoY Change | — | — | — | — | -33.5% | -33.5% | -33.5% | -33.5% | -144.7% | -83.5% | -162.4% | -181.0% | -49.5% | -65.9% | -137.4% |
Range-$368.00M – $373.50M
CAGR-0.4%
Avg YoY Growth-87.1%
Median YoY Growth-65.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — other (income) expense, net?
- Johnson & Johnson (JNJ) reported innovative medicine — other (income) expense, net of -$368.00M in Q3 2025.
- How has Johnson & Johnson's innovative medicine — other (income) expense, net changed year-over-year?
- Johnson & Johnson's innovative medicine — other (income) expense, net decreased by 137.4% year-over-year, from -$155.00M to -$368.00M.
- What is the long-term trend for Johnson & Johnson's innovative medicine — other (income) expense, net?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — other (income) expense, net has grown at a -46.6% compound annual growth rate (CAGR), from $1.49B to -$426.00M.
- What does innovative medicine — other (income) expense, net mean?
- Miscellaneous income or expenses for the Innovative Medicine segment that are not part of core operations.